Insider · CIK 0001959160
Ying Luo
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing May 7, 2026, latest May 7, 2026.
In brief
Ying Luo files SEC Form 4 as CEO and director at GYRE (GYRE THERAPEUTICS, INC.). Since May 7, 2026, Ying Luo has reported 0 open-market buys worth $0 and 1 open-market sell worth $83k, the latest filed on May 7, 2026.
A track record needs three past buys with six months of prices behind them; Ying Luo has 0, so none is measured yet.
The newest scored trade: sold $83k of GYRE on May 5, 2026, filed May 7, 2026, scored 22 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $83k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GYRE: GYRE THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | GYRE THERAPEUTICS, INC. | $83k 10,315 shares | -0% | +17% from low-32% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jun 10, 2026 |
| May 5, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -179 | $8.01 | $1,434 | 2,575,362 | May 7, 2026 |
| May 6, 2026 | GYRE GYRE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: By Spouse10b5-1 | -10,136 | $8.04 | $81k | 2,565,226 | May 7, 2026 |
| Oct 30, 2023 | GYRE GYRE THERAPEUTICS, INC. | JOther Common Stockindirect: By Spouse | +2,840,376 | - | - | 2,840,376 | Nov 22, 2023 |
| Nov 20, 2023 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +3,350,897 | $0.00 | $0 | 3,350,897 | Nov 22, 2023 |
| Nov 20, 2023 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Spouse | +2,262,755 | $0.00 | $0 | 2,262,755 | Nov 22, 2023 |
| Oct 31, 2023 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,866 | $0.00 | $0 | 1,866 | Nov 1, 2023 |
Questions about Ying Luo
Answered from the filings on this page, as of the latest one.
Is Ying Luo buying or selling?
In the last 12 months Ying Luo reported 0 open-market buys worth $0 and 1 open-market sell worth $83k on SEC Form 4; the latest was sold $83k of GYRE on May 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Ying Luo's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ying Luo has 0.
Where does Ying Luo file Form 4?
Ying Luo has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.